Biote Announces Purchase of Shares by Directors and CEO
Biote Corp (NASDAQ: BTMD) announced significant insider stock purchases, with several Board of Directors members and CEO Bret Christensen collectively acquiring approximately 260,000 shares through open market transactions.
Executive Chairman Marc Beer expressed confidence in the company's business strategy and long-term outlook, specifically highlighting CEO Christensen's capabilities to implement decisive changes for business growth. Beer emphasized Christensen's extensive background in diagnostic, therapeutic, and medical device healthcare sectors as key qualifications for leading Biote's expansion.
Biote Corp (NASDAQ: BTMD) ha annunciato significativi acquisti di azioni da parte di insider, con diversi membri del Consiglio di Amministrazione e il CEO Bret Christensen che hanno acquisito collettivamente circa 260.000 azioni tramite transazioni sul mercato aperto.
Il Presidente Esecutivo Marc Beer ha espresso fiducia nella strategia aziendale e nelle prospettive a lungo termine dell'azienda, sottolineando in particolare le capacità del CEO Christensen di attuare cambiamenti decisivi per la crescita dell'azienda. Beer ha enfatizzato l'ampio background di Christensen nei settori diagnostico, terapeutico e dei dispositivi medici come qualifiche chiave per guidare l'espansione di Biote.
Biote Corp (NASDAQ: BTMD) anunció importantes compras de acciones por parte de personas internas, con varios miembros de la Junta Directiva y el CEO Bret Christensen adquiriendo colectivamente aproximadamente 260,000 acciones a través de transacciones en el mercado abierto.
El Presidente Ejecutivo Marc Beer expresó confianza en la estrategia comercial de la empresa y en las perspectivas a largo plazo, destacando específicamente las capacidades del CEO Christensen para implementar cambios decisivos para el crecimiento del negocio. Beer enfatizó el amplio historial de Christensen en los sectores de diagnóstico, terapéutico y de dispositivos médicos como calificaciones clave para liderar la expansión de Biote.
Biote Corp (NASDAQ: BTMD)는 몇몇 이사회의 멤버들과 CEO 브렛 크리스텐슨이 총 260,000주를 공개 시장 거래를 통해 공동으로 매입했다고 발표했습니다.
최고 의장 마크 비어는 회사의 비즈니스 전략과 장기 전망에 대한 신뢰를 표명하며, 특히 CEO 크리스텐슨이 비즈니스 성장을 위한 결정적인 변화를 구현할 수 있는 능력을 강조했습니다. 비어는 진단, 치료 및 의료 기기 분야에서의 크리스텐슨의 폭넓은 배경이 Biote의 확장을 이끌기 위한 핵심 자격이라고 강조했습니다.
Biote Corp (NASDAQ: BTMD) a annoncé des achats d'actions significatifs par des initiés, plusieurs membres du Conseil d'Administration et le PDG Bret Christensen ayant collectivement acquis environ 260 000 actions par le biais de transactions sur le marché ouvert.
Le Président Exécutif Marc Beer a exprimé sa confiance dans la stratégie commerciale de l'entreprise et ses perspectives à long terme, soulignant en particulier les capacités du PDG Christensen à mettre en œuvre des changements décisifs pour la croissance de l'entreprise. Beer a souligné que l'expérience approfondie de Christensen dans les secteurs du diagnostic, du thérapeutique et des dispositifs médicaux constitue des qualifications clés pour diriger l'expansion de Biote.
Biote Corp (NASDAQ: BTMD) gab bekannt, dass bedeutende Insider-Aktienkäufe getätigt wurden, wobei mehrere Mitglieder des Vorstands und CEO Bret Christensen gemeinsam etwa 260.000 Aktien durch Transaktionen auf dem offenen Markt erworben haben.
Der Executive Chairman Marc Beer äußerte Vertrauen in die Geschäftsstrategie des Unternehmens und die langfristigen Aussichten und hob insbesondere die Fähigkeiten von CEO Christensen hervor, entscheidende Veränderungen für das Unternehmenswachstum umzusetzen. Beer betonte, dass Christensen über umfangreiche Erfahrungen in den Bereichen Diagnostik, Therapie und medizinische Geräte verfügt, die als entscheidende Qualifikationen für die Leitung der Expansion von Biote gelten.
- Significant insider buying of 260,000 shares demonstrates management's confidence
- Strong vote of confidence from Board and CEO in company's strategy
- CEO's healthcare expertise spans diagnostic, therapeutic, and medical device sectors
- None.
Marc Beer, Biote Executive Chairman, said, "These share purchases underscore the collective confidence of Biote’s Board members and CEO Bret Christensen in the Company’s business strategy and long-term outlook. The board is very confident in Bret’s ability to make decisive and material changes at Biote to grow our business. With his deep expertise spanning the diagnostic, therapeutic and medical device health care sectors, we believe Bret is exceptionally qualified to lead Biote’s next level of business growth.”
About Biote
Biote is transforming healthy aging through innovative, personalized hormone optimization and therapeutic wellness solutions delivered by Biote-certified medical providers. Biote trains practitioners to identify and treat early indicators of aging conditions, an underserved global market, providing affordable symptom relief for patients and driving clinic success for practitioners.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “may,” “can,” “should,” “will,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “hope,” “believe,” “seek,” “target,” “continue,” “could,” “might,” “ongoing,” “potential,” “predict,” “would” and other similar expressions, are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and their patients; our customers’ reliance on certain third parties to support the manufacturing of bio-identical hormones for prescribers; our and our customers’ sensitivity to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; our ability to grow our business; the significant competition we face in our industry; the impact of strategic acquisitions and the implementation of our growth strategies; our limited operating history; our ability to protect our intellectual property; the heavy regulatory oversight in our industry; changes in applicable laws or regulations; changes to international tariffs; the inability to profitably expand in existing markets and into new markets; the possibility that we may be adversely impacted by other economic, business and/or competitive factors, including the impact of hurricane and other natural disasters; and future exchange and interest rates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and other risks and uncertainties described in the “Risk Factors” section of the Biote’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, each filed or to be filed with the Securities and Exchange Commission (the “SEC”) and other documents filed by Biote from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Biote assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Biote does not give any assurance that it will achieve its expectations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250318177308/en/
Investor Relations:
Eric Prouty
AdvisIRy Partners
eric.prouty@advisiry.com
Media:
Press@biote.com
Source: biote Corp.
FAQ
How many shares did Biote (BTMD) insiders purchase in the recent buying activity?
Who participated in the recent BTMD stock purchase?
What does the insider buying indicate about BTMD's future outlook?
What is Biote's (BTMD) current business focus?
